drugset / Trial / NCT05821478
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
Phase 3
Recruiting
92 enrolled
Institut Pasteur
Assistance Publique Hopitaux De Marseille · collabCentre Hospitalier Universitaire de Caen · collabHôpital Necker-Enfants Malades · collabMinistry of Health, France · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
Timeline
- Start
- 2025-05-22
- Primary completion
- 2027-02-28
- Completion
- 2028-02-27
Publications
- Background Guet-Revillet H, Jais JP, Ungeheuer MN, Coignard-Biehler H, Duchatelet S, Delage M, Lam T, Hovnanian A, Lortholary O, Nassif X, Nassif A, Join-Lambert O. The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study. Clin Infect Dis. 2017 Jul 15;65(2):282-291. doi: 10.1093/cid/cix285.
- Background Guet-Revillet H, Coignard-Biehler H, Jais JP, Quesne G, Frapy E, Poiree S, Le Guern AS, Le Fleche-Mateos A, Hovnanian A, Consigny PH, Lortholary O, Nassif X, Nassif A, Join-Lambert O. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis. 2014 Dec;20(12):1990-8. doi: 10.3201/eid2012.140064.
- Background Join-Lambert O, Coignard H, Jais JP, Guet-Revillet H, Poiree S, Fraitag S, Jullien V, Ribadeau-Dumas F, Theze J, Le Guern AS, Behillil S, Lefleche A, Berche P, Consigny PH, Lortholary O, Nassif X, Nassif A. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011 Feb;222(1):49-58. doi: 10.1159/000321716. Epub 2010 Nov 25.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceftriaxone | Other / unclassified | 2 g | Intravenous |
| Comparator | Lymecyclin and corresponding placebos of the experimental arm | Unknown | 452 mg | Oral |
| Subject | Metronidazole | Small molecule | 1500 mg | Oral |
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Rifampin | Small molecule | 10 mg/kg | Oral |